A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

被引:453
作者
Kishnani, Priya S.
Hwu, Wuh-Liang
Mandel, Hanna
Nicolino, Marc
Yong, Florence
Corzo, Deyanira
机构
[1] Duke Univ, Div Med Genet, Dept Pediat, Med Ctr, Durham, NC 27710 USA
[2] Natl Taiwan Univ, Coll Med, Dept Pediat & Med Genet, Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Technion Israel Inst Technol, Rambam Med Ctr, Metab Unit, Meyers Childrens Hosp,Fac Med, Haifa, Israel
[4] Univ Hosp Debrousse, Div Pediat Endocrinol & Metab, Lyon, France
[5] Genzyme Corp, Cambridge, MA USA
关键词
D O I
10.1016/j.jpeds.2005.11.033
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To characterize the natural progression of infantile-onset Pompe disease. Study design Retrospective chart reviews of 168 patients with documented acid a-glucosidase deficiency and symptom onset by 12 months of age; Kaplan-Meier analysis of total and ventilator-free survival time; Cox proportional hazards regression modeling of mortality risk factors. Results The median age at symptom onset was 2.0 months (range 0 to 12 months), 4.7 months at diagnosis (range: prenatal to 4.2 months). 5.9 months at first ventilator support (range 0.1 to 31.1 months), and 8.7 months at death (range 0.3 to 73.4 months). Survival rates at 12 months of age were 25.7% overall and 16.9% ventilator-free; at 18 months 12.3% and 6.7%. Cardiomegaly (92%), hypotonia (88%), cardiomyopathy (88%), respiratory distress (78%), muscle weakness (63%), feeding difficulties (57%), and failure to thrive (53%) appeared after a median age of similar to 4.0 months. Multiple covariate analysis confirmed that early symptom onset increased risk of early death. Conclusion Despite frequent therapeutic interventions, infantile-onset Pompe disease remains lethal.
引用
收藏
页码:671 / 676
页数:6
相关论文
共 19 条
[1]   Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial [J].
Amalfitano, A ;
Bengur, AR ;
Morse, RP ;
Majure, JM ;
Case, LE ;
Veerling, DL ;
Mackey, J ;
Kishnani, P ;
Smith, W ;
McVie-Wylie, A ;
Sullivan, JA ;
Hoganson, GE ;
Phillips, JA ;
Schaefer, GB ;
Charrow, J ;
Ware, RE ;
Bossen, EH ;
Chen, YT .
GENETICS IN MEDICINE, 2001, 3 (02) :132-138
[2]  
[Anonymous], 2000, CDC GROWTH CHARTS US
[3]  
[Anonymous], EPIDEMIOLOGY CONGENI
[4]   Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling [J].
Ausems, MGEM ;
Verbiest, J ;
Hermans, MMP ;
Kroos, MA ;
Beemer, FA ;
Wokke, JHJ ;
Sandkuijl, LA ;
Reuser, AJJ ;
van der Ploeg, AT .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (06) :713-716
[5]  
Cox D. R., 1984, Analysis of survival data
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
Hirschhorn R, 2004, PEDIATR RES, V55, p272A
[8]  
Hirschhorn R., 2001, METABOLIC MOL BASES, P3389
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
Kishnani P, 2003, PEDIATR RES, V53, p259A